UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to UroGen Pharma Ltd.'s fourth quarter 2025 earnings call. At this time, all participants are in a listen-only mode.
Urogen Pharma Ltd. (URGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Paradigm Biocapital Advisors Senai Asefaw | 4,473,648 | $104,772,836 | +7% | 2.67% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 2,199,652 | $51,515,850 | 0.26% | |
| 3. | SilverArc Capital Devesh Gandhi | 1,738,821 | $40,723,188 | +11% | 5.66% |
| 4. | D E Shaw D. E. Shaw | 962,624 | $22,544,654 | +9% | 0.01% |
| 5. | BioImpact Capital Mpm Capital | 941,378 | $22,047,073 | +598% | 2.52% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.10 | 160 | $2,096.00 | 21,997 | 2021-11-18 | Filing | |
| $15.85 | 2,500 | $39,625.00 | 2,500 | 2021-05-17 | Filing | |
| $15.71 | 2,500 | $39,275.00 | 2,500 | 2021-05-17 | Filing | |
| $18.50 | 10,000 | $185,000.00 | 229,117 | 2020-12-14 | Filing | |
| $28.00 | 7,530 | $210,840.00 | 16,548 | 2019-11-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.69 | 3,217 | $63,342.73 | 55,588 | 2026-02-03 | Filing | |
| $19.69 | 1,608 | $31,661.52 | 51,326 | 2026-02-03 | Filing | |
| $19.69 | 2,654 | $52,257.26 | 52,934 | 2026-02-03 | Filing | |
| $19.69 | 3,686 | $72,577.34 | 144,985 | 2026-02-03 | Filing | |
| $19.69 | 1,843 | $36,288.67 | 148,671 | 2026-02-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 72,286 | $1,299,702 | 0% | |
| 2. | 34,701 | $623,924 | 0.15% | |
| 3. | 22,223 | $399,523 | 0% | |
| 4. | 14,300 | $257,114 | 0% | |
| 5. | 10,469 | $188,233 | 0% |
News See All
UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs
On November 6, 2025, UroGen Pharma Ltd. (NASDAQ:URGN) reported its Q3 2025 results, highlighting strong growth in demand alongside its steady commercial expansion.
10 Best Small-Cap Biotech Stocks to Buy According to Analysts
Small-cap biotech stocks are marking their latest resurgence, attracting renewed investor attention.
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2025 Earnings Call Transcript
Operator: Good morning, and thank you for standing by. Welcome to the UroGen Pharma Third Quarter 2025 Earnings Call. [Operator Instructions] Please be advised today's conference is being recorded.
UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the UroGen Pharma Second Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded.
UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology
UroGen Pharma Ltd. (NASDAQ:URGN) is one of the Stocks With Huge Catalysts on the Horizon. On June 2, UroGen Pharma Ltd.
10 Stocks With Huge Catalysts on the Horizon
The August 1 tariff deal is approaching; however, the market seems to have gotten used to the tariff headlines.
UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer
UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best hot stocks to buy according to Wall Street analysts.
11 Best Hot Stocks to Buy According to Wall Street Analysts
On July 1, Ralph Schlosstein, Evercore's chairman emeritus and BlackRock's co-founder, joined 'Closing Bell Overtime' on CNBC to talk about his outlook for markets heading into the second half of the ...
H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy
UroGen Pharma Ltd. (NASDAQ:URGN) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at H.C. Wainwright significantly raised the rating for UroGen Pharma Ltd.